Hydrocortisone Replacement Dosing: The Complete Clinical Guide

What Is the Standard Hydrocortisone Replacement Dose?

The Endocrine Society's 2016 Clinical Practice Guideline recommends 15 to 25 mg of oral hydrocortisone daily for adults with primary adrenal insufficiency, split across two or three doses timed to mirror the normal diurnal cortisol curve [1]. Most endocrinologists start at 15 to 20 mg and adjust based on clinical response rather than serum cortisol levels alone.

Why Weight-Based Dosing Matters

Body surface area correlates more tightly with cortisol secretion rate than body weight alone. A landmark pharmacokinetic study published in the Journal of Clinical Endocrinology and Metabolism (Filipsson et al., 2006) showed that the mean cortisol production rate in healthy adults is approximately 9.9 mg/m² per day, which translates to roughly 5.7 to 7.4 mg per day in absolute terms [2]. Because oral hydrocortisone bioavailability is only about 96% with significant inter-individual variation in absorption and clearance, the clinical replacement dose must exceed the pure physiologic production figure, landing in the 15 to 25 mg window.

Patients with a body surface area above 2.0 m² may need doses at the upper end or slightly above. Smaller adults, especially women, often achieve adequate replacement at 10 to 15 mg per day.

Dose Timing Protocol

Replicating the natural cortisol peak (6 to 8 am) reduces fatigue and prevents afternoon adrenal-deficiency symptoms. A two-dose schedule commonly used in clinical practice is:

• Dose 1: 10 to 15 mg on waking (6 to 8 am)
• Dose 2: 5 to 10 mg at noon to 2 pm

A three-dose schedule adds a small 2.5 to 5 mg dose in the late afternoon (around 4 to 5 pm), which helps patients who experience late-day fatigue without significantly disrupting sleep. An evening dose after 6 pm is generally avoided because residual cortisol can suppress sleep architecture [1].

Stress Dose Steroids: When and How Much

Any physiologic stressor that would normally trigger a healthy adrenal gland to surge cortisol output requires a preemptive dose increase in patients on replacement therapy. The principle is simple. The body needs more cortisol under stress, and the diseased or surgically absent adrenal gland cannot supply it.

Minor Illness and the Sick Day Rules for Addison's Disease

The standard sick day rule, endorsed by both the Endocrine Society and the Society for Endocrinology, instructs patients to double or triple their usual daily hydrocortisone dose at the first sign of illness, particularly fever above 38°C, significant fatigue, nausea, or any infection requiring a physician visit [1, 3].

Specifically:

• Fever or systemic illness: Double the total daily dose, spread across the same number of daily intervals, for 2 to 3 days or until recovery.
• Vomiting or diarrhea: Oral absorption is unreliable. Patients should inject hydrocortisone 100 mg IM (from an emergency kit) and seek immediate medical attention.
• Strenuous physical exertion (marathon running, heavy manual labor in heat): An extra 5 to 10 mg dose taken before or during the activity is often sufficient.

A 2014 audit published in the European Journal of Endocrinology (Smans et al.) found that fewer than 50% of patients with adrenal insufficiency had received written sick day instructions from their care team, yet patients who had clear written protocols had significantly lower rates of adrenal crisis hospitalizations [4].

Surgical and Procedural Stress Dosing

The degree of surgical stress determines the hydrocortisone augmentation. Three tiers are widely accepted [1, 5]:

Minor procedures (e.g., dental extraction, colonoscopy without general anesthesia): Take the usual morning dose. An additional 5 to 10 mg before the procedure is reasonable.

Moderate surgical stress (e.g., cholecystectomy, hernia repair under general anesthesia): Hydrocortisone 50 to 75 mg IV on the day of surgery, then taper back to maintenance over 1 to 2 days.

Major surgery (e.g., cardiac surgery, abdominal surgery with prolonged anesthesia): Hydrocortisone 100 mg IV bolus at induction, followed by 50 mg IV every 8 hours for 24 hours, then taper to double oral maintenance over 2 days, then return to baseline.

These figures align with the Society for Endocrinology guidance and a widely cited review by Woodcock et al. In Clinical Medicine (2020) [5, 6].

Recognizing and Treating Adrenal Crisis

Adrenal crisis is a life-threatening emergency. The clinical triad is hypotension, hyponatremia, and profound fatigue or altered consciousness in a patient on glucocorticoid replacement. The treatment is immediate:

1. Hydrocortisone 100 mg IV or IM bolus without delay.
2. Normal saline (0.9% NaCl) 1 liter IV over the first hour.
3. Continuous monitoring and repeat hydrocortisone 50 to 100 mg IV every 6 to 8 hours for the first 24 hours [1].

A 2016 population study in the Journal of Clinical Endocrinology and Metabolism (Rushworth et al.) estimated the crisis rate at 6.3 per 100 patient-years in primary adrenal insufficiency, with mortality around 0.5 per 100 patient-years in undertreated populations [7]. Carrying a pre-loaded hydrocortisone emergency injection kit reduces this risk substantially.

Hydrocortisone Versus Other Glucocorticoids

Not all glucocorticoid replacements are equal. Hydrocortisone is preferred for adrenal insufficiency precisely because its short half-life (about 8 hours) allows dose timing to mimic the diurnal rhythm. Prednisolone and prednisone have longer half-lives and are harder to titrate physiologically, though they are used when cost or dosing frequency is a barrier.

Glucocorticoid Potency Equivalences

| Drug | Equivalent anti-inflammatory dose | Half-life | |---|---|---| | Hydrocortisone | 20 mg | ~8 hours | | Prednisolone | 5 mg | ~18 hours | | Prednisone | 5 mg | ~18 hours (prodrug) | | Dexamethasone | 0.75 mg | ~36 hours | | Methylprednisolone | 4 mg | ~18 hours |

Source: FDA prescribing information and standard pharmacology references [8, 9].

Dexamethasone has no mineralocorticoid activity, making it unsuitable as a sole replacement agent in primary adrenal insufficiency. Patients with Addison's disease also require fludrocortisone 0.05 to 0.2 mg daily for mineralocorticoid replacement, a fact sometimes overlooked when transitioning patients from high-dose prednisone [1].

Modified-Release Hydrocortisone

Plenadren (modified-release hydrocortisone), approved in the European Union, delivers a once-daily dose that mimics the morning cortisol peak more closely than conventional immediate-release tablets. A randomized crossover trial by Johannsson et al. (2012, N=64) in Journal of Clinical Endocrinology and Metabolism showed that modified-release hydrocortisone reduced total daily cortisol exposure by about 15% while maintaining quality of life scores, compared to three-times-daily immediate-release dosing [10]. This formulation is not yet FDA-approved in the United States as of early 2025, but is available through some compounding pharmacies.

Tapering Prednisone Safely

Patients who have been on supraphysiologic glucocorticoid doses for more than 3 weeks develop hypothalamic-pituitary-adrenal (HPA) axis suppression. Tapering too quickly risks precipitating iatrogenic adrenal insufficiency.

When HPA Suppression Occurs

HPA suppression is probable when a patient has taken prednisone 20 mg or more per day for more than 3 weeks, or when they show Cushingoid features regardless of dose or duration [11]. An 8 am serum cortisol below 3 mcg/dL after holding the morning prednisone dose confirms suppression. Values between 3 and 10 mcg/dL are indeterminate and warrant a cosyntropin stimulation test (250 mcg IV, peak cortisol target above 18 mcg/dL at 30 or 60 minutes) [1, 12].

The Prednisone Taper Protocol

No single universal taper schedule exists, but the following framework is widely used and consistent with American College of Rheumatology guidance [11]:

Phase 1 (supraphysiologic to physiologic range): Reduce prednisone by 2.5 to 5 mg every 1 to 2 weeks until reaching approximately 5 mg per day. Rate depends on the underlying disease being treated.

Phase 2 (physiologic range to discontinuation): Below 5 mg prednisone per day, reduce by 1 mg every 2 to 4 weeks. This phase is the most likely to provoke withdrawal symptoms and requires slower pacing.

Switching to hydrocortisone for the final phase: Some endocrinologists switch from prednisone 5 mg to hydrocortisone 20 mg at this stage to allow finer titration. This approach is supported by the Endocrine Society guideline [1].

Symptoms of glucocorticoid withdrawal include fatigue, myalgia, arthralgia, nausea, and postural hypotension. These can occur even when serum cortisol is measurably normal, a phenomenon sometimes called steroid withdrawal syndrome. It is distinct from true adrenal insufficiency but can be difficult to distinguish clinically.

Monitoring During a Taper

Check an 8 am serum cortisol after the patient has been on 5 mg prednisone or less for at least 2 weeks, with the prednisone dose held the prior evening. A level above 10 mcg/dL suggests adequate recovery. Above 18 mcg/dL generally clears the patient for discontinuation, though the cosyntropin stimulation test provides higher certainty [12]. The Society for Endocrinology notes that full HPA recovery after prolonged high-dose glucocorticoid use can take 6 to 12 months [3].

Special Populations and Dose Adjustments

Standard dosing assumptions do not apply uniformly across all patients.

Pregnancy

Hydrocortisone requirements increase during the third trimester because placental 11β-hydroxysteroid dehydrogenase type 2 metabolizes some cortisol. The Endocrine Society recommends increasing the hydrocortisone dose by 20 to 40% in the third trimester and administering stress-dose hydrocortisone (100 mg IV) at the onset of active labor [1]. A review in Clinical Endocrinology (Lebbe et al., 2011) confirmed that maternal adrenal insufficiency managed with appropriate dose escalation during labor carries no increase in fetal adverse outcomes [13].

Thyroid Disease

Hypothyroidism slows cortisol clearance, meaning a given dose produces higher and longer exposure. Conversely, hyperthyroidism or thyroid hormone replacement accelerates clearance. Starting levothyroxine in a patient with unrecognized adrenal insufficiency can precipitate adrenal crisis by increasing cortisol metabolism before the HPA axis can compensate. Adrenal status should be assessed before starting thyroid replacement in any patient suspected of having combined hypopituitarism [1].

Elderly Patients

Renal and hepatic clearance of hydrocortisone decline with age. Older patients may achieve adequate replacement at the lower end of the dose range (10 to 15 mg per day). Over-replacement in older adults accelerates bone mineral density loss; a study in Osteoporosis International (Zelissen et al., 1994) found that patients on hydrocortisone above 20 mg per day had measurably lower lumbar spine bone density than age-matched controls [14].

Secondary and Tertiary Adrenal Insufficiency

Patients with pituitary or hypothalamic disease causing adrenal insufficiency have an intact zona glomerulosa and do not require fludrocortisone. Their hydrocortisone doses also tend to be slightly lower, typically 15 to 20 mg per day, because some residual pituitary ACTH secretion may remain [1].

Monitoring Hydrocortisone Replacement: Avoiding Over- and Under-Treatment

Serum cortisol levels measured on replacement therapy are difficult to interpret because they reflect recent dose timing rather than overall adequacy. Clinicians rely instead on clinical and biochemical markers.

Clinical Signs of Under-Replacement

Persistent fatigue despite adequate sleep, salt craving, postural dizziness, hyperpigmentation (in primary adrenal insufficiency), weight loss, and hyponatremia all suggest under-replacement. Plasma ACTH above 200 pg/mL in a patient on replacement is a strong signal the dose is inadequate [1].

Clinical Signs of Over-Replacement

Weight gain, hypertension, glucose intolerance, easy bruising, and reduced bone mineral density indicate Cushingoid exposure. The goal is the lowest dose that resolves symptoms. An annual bone density scan (DEXA) is reasonable for patients on replacement therapy long-term, per the Endocrine Society guideline [1].

24-Hour Urine Free Cortisol and Serum Cortisol Day Curves

A serum cortisol day curve, with samples taken at the time of each dose and at the trough between doses, gives the most complete picture of cortisol exposure on replacement. Target area under the curve values for a normal diurnal profile have been described in research settings (Lovas et al., 2009, European Journal of Endocrinology, N=28), though this technique is not yet standard in most outpatient practices [15]. Salivary cortisol sampling at home is an emerging alternative under active investigation.

Patient Education and Emergency Preparedness

Every patient on hydrocortisone replacement should carry a medical alert card or bracelet and an emergency hydrocortisone injection kit. The kit typically contains a hydrocortisone 100 mg powder-for-injection vial with a saline diluent, and patients (or a family member) should be trained in IM injection technique annually.

The Addison's Clinical Advisory Panel (ACAP) published a consensus statement in 2016 recommending that every patient with adrenal insufficiency receive written sick day rules at diagnosis and at every annual review [3]. Training a family member or close contact in emergency injection is associated with faster treatment initiation and reduced emergency department delays.

A 24-hour wearable cortisol monitor is under development in several research programs. Early-phase data from a device-linked study reported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) suggest real-time cortisol sensing may enable closed-loop dosing algorithms within the next decade, similar to insulin pump technology in type 1 diabetes [16].